EUR
Swedish French Dutch Spanish English
On the Capita cell, you can invest in shares of medical startups with x10+ return potential.
Capital Cell selects promoters through a multi-step screening focused on scientific, commercial, and legal quality. Promoters must submit detailed project, team, and financial information, which is reviewed by Capital Cell and its expert BioExpert Network for feasibility and investment merit. If approved, the promoter agrees on campaign terms and completes legal and financial due diligence. Before a public launch, a private pre-campaign must demonstrate traction, including a committed lead investor (around 15%), at least 20% of the target reserved, and interest from a minimum number of investors. Capital Cell may refuse publication if documentation, investor interest, or the promoter’s promotional capacity is insufficient.
License/regulation: CAPITAL CELL licensed under European Crowdfunding Service Providers (ECSP) regulation
Capital Cell operates as an Equity crowdfunding platform offering investors to invest in startups and early-stage companies through acquiring company shares. On the other hand offering companies am alternative fundraising tool to raise funds from a large pool of investors.
On Capital Cell you can invest in European startups from healthcare and biotech industries
When investing on Capital Cell you invest in early-stage companies which makes it a high-risk investment since statistically 9 of 10 early-stage companies fail. You as an investor have to carefully evaluate such investments including product, product-market fit, company team and their ability to successfully develop a company, total addressable and reachable market and company growth potential, and other risks depending on business specifics.
This platform have no rating yet. Be the first to rate!
Healthcare